OPKO Health Beats Q4 Earnings Estimates

Biotechnology company OPKO Health reports Q4 results, with earnings per share exceeding analyst forecasts.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

OPKO Health (NASDAQ:OPK), a diversified global healthcare company, announced its fourth-quarter financial results on Thursday. The company reported earnings per share of ($0.04), beating the consensus estimate of ($0.07) by $0.03. However, OPKO Health's revenue declined 19.1% year-over-year to $148.5 million.

Why it matters

OPKO Health's better-than-expected earnings results come as the company continues to focus on its diagnostics and pharmaceutical development businesses. The company's performance is closely watched by investors as it navigates the challenges facing the healthcare industry.

The details

OPKO Health reported a negative net margin of 28.10% and a negative return on equity of 13.67% for the quarter. The company's revenue decline was attributed to the divestiture of certain assets. OPKO Health also provided an update on its ModeX clinical programs, including dose escalation studies showing tolerability and early efficacy signals for its MDX-2001 candidate.

  • OPKO Health reported its Q4 2026 earnings results on Thursday, February 27, 2026.

The players

OPKO Health

A diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development.

Got photos? Submit your photos here. ›

The takeaway

OPKO Health's Q4 2026 earnings results demonstrate the company's ongoing efforts to streamline its operations and invest in its pharmaceutical development pipeline, despite facing some financial headwinds. Investors will be closely watching the company's progress as it navigates the evolving healthcare landscape.